Digital Portal Strengthens Patient Engagement in Cancer Clinical Trials
Among patients who used PEP, 84% reported a positive experience, 96% said it was easy to access, and 93% found surveys easy to complete
@harvardmed#IPMoncology#cancer#clinicaltrialhubs.li/Q04lgTx90
“I want people to see the massive ways that we could treat cancer,” Prof. Neil Forbes tells Inside @Inside_PM about a UMass study that highlights a new approach to fighting cancer. “There are a lot of possibilities that I think are untapped.” bit.ly/4olmZVT
Lipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer Detection
@AOA_Dx combined AI with multi-omic ovarian cancer biomarkers to make the first ovarian cancer diagnostic breakthrough in 35 years
#AI#ovariancancer#biomarkershubs.li/Q04lfrG60
Unlock strategies to reduce drug development risk by downloading our free eBook, “Protein Biomarkers in Practice,” featuring insights from top pharma leaders. Sponsored by Olink: hubs.ly/Q04fZPRt0#ProteinBiomarker#DrugDevelopment#Proteomics
Phase Ib/IIa for Hepatitis B Epigenetic Silencer Shows Best-in-Class Potential
@tunetx_news' CEO John McHutchison, MD, discusses TUNE-401's clinical data, the first drug to silence episomal and integrated HBV DNA
#biomarkers#HepatitisB#epigeneticshubs.li/Q04l21NP0
Signatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care Pathway
Signatera ctDNA testing bridges the gap from uncertainty to actionability by answering meaningful questions at each stage of the patient’s journey.
Sponsored: @NateraGeneticshubs.li/Q04kN72X0
Discover cutting-edge NGS in myeloid malignancy testing with insights from a leading Portuguese center. Join our free webinar on June 30, sponsored by @SOPHiAGENETICS. Register: hubs.li/Q04jXGkl0#NGS#CancerTesting
Genome Wide Analysis Broadens Genetic Knowledge of Anxiety
A large meta-analysis has uncovered new information about the genetics of anxiety, including a number of new variants linked to the condition
@KingsCollegeLon#anxietydisorders#geneticvariantshubs.li/Q04kJYrB0
GLP-1 Drugs Linked to Lower Rates of Substance Use Disorders
GLP-1 RA medications may influence dopamine signaling and other neural pathways that drive cravings not just for food but other substances
@UTEP#GLP1#substanceusedisorder#obesityhubs.li/Q04kJD390
Microglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to Dementia
A microglial transition in AD may influence whether the accumulation of amyloid-β plaques and tau pathology progresses to #dementia@UKDRI@muna_tx#Alzheimershubs.li/Q04ks6yf0
New Tumor Survival Mechanism Revealed in Aggressive ALT Cancers
A new study reveals centromere-derived chromatin signatures at #telomeres in ALT cancers, uncovering a novel mechanism supporting tumor survival
@ArbelyYael@PittTweet#DNA#chromosomehubs.li/Q04klsFh0